| Pair Name | Schisandrin B, Panitumumab | ||
| Phytochemical Name | Schisandrin B (PubChem CID: 108130 ) | ||
| Anticancer drug Name | Panitumumab (PubChem CID: / ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Schisandrin B, Panitumumab | |||
| Disease Info | [ICD-11: 2B91.Z] | Colorectal cancer | Investigative | |
| Biological Phenomena | Induction-->Autophagy | |||
| Gene Regulation | Up-regulation | Activity | CASP3 | hsa836 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Down-regulation | Expression | MAP1LC3B | hsa81631 | |
| Down-regulation | Expression | BECN1 | hsa8678 | |
| In Vitro Model | Caco-2 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0025 |
| HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 | |
| HT-29 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0320 | |
| Result | This novel combination therapy against CRC, allows the reduction of panitumumab dose to guard against its adverse effects. | |||
| No. | Title | Href |
|---|---|---|
| 1 | The potential effect of Schisandrin-B combination with panitumumab in wild-type and mutant colorectal cancer cell lines: Role of apoptosis and autophagy. J Biochem Mol Toxicol. 2023 May;37(5):e23324. doi: 10.1002/jbt.23324. | Click |
